The objective of this study was to test the hypothesis that activation of soluble guanylyl cyclase and increased cGMP formation in the brain would improve task acquisition in cognitively impaired animals. We evaluated the effects of a novel nitrate ester, GT 715 (2,3-dinitrooxy-(2,3-bis-nitrooxypropyldisulfanyl)-propane), in scopolamine-induced impairment of task acquisition in the Morris water maze. GT 715 improved task acquisition in scopolamine-pretreated animals in a timeand dose-dependent manner, whereas the prototypical nitrate ester, glyceryl trinitrate (GTN), was ineffective. GT 715 also was more effective and more potent than GTN for activation of hippocampal guanylyl cyclase. The results of this study therefore suggest that stimulation of cerebral soluble guanylyl cyclase activity may be an effective strategy to improve learning and memory performance in individuals in whom cognitive abilities are impaired by injury, disease, or ageing. NeuroReport
INTRODUCTION
The soluble isoform of guanylyl cyclase (sGC) can be activated by nitric oxide (NO), the product of the enzyme NO synthase (NOS), leading to the formation of cGMP. In many regions of the CNS, NOS activation and elevation of tissue cGMP levels follows as a consequence of activation of both the NMDA subtype of excitatory amino acid receptors and cholinergic muscarinic receptor subtypes [1± 4] . NO is recognized as an intercellular messenger molecule in the CNS, and the NO/sGC/cGMP signal transduction system is considered to be important for modulating synaptic transmission and plasticity in brain regions such as the hippocampus, cerebral cortex, and cerebellum [5, 6] .
Several recent studies have provided experimental evidence that the sGC/cGMP signal transduction system is important for acquisition of new learning and memory. In a passive avoidance learning paradigm with rats, training was associated with an increase in the level of cGMP in the hippocampus, and administration of a membrane permeant cGMP analog enhanced memory performance [7] . Conversely, in the same paradigm, inhibition of either sGC activity or protein kinase G immediately post-training blocked memory formation [8] . Inhibition of NOS with 7-nitroindazole impaired object recognition memory in rats, whereas treatment with zaprinast, a selective cGMP phosphodiesterase inhibitor, both facilitated object recognition and reversed the memory de®cit induced by 7-nitroindazole [9] . The results of animal studies suggesting a role for the NO/sGC/cGMP signal transduction system in learning and memory are supported by numerous in vitro studies showing that long-term potentiation in the hippocampus can be blocked by inhibition of sGC [10±12] , and that NO and cGMP can induce long-lasting enhancement of presynaptic neurotransmitter release [10, 13] .
Alzheimer's disease (AD) is characterized by disruption of both excitatory amino acid and cholinergic neurotransmission. Moreover, NO-stimulated sGC activity is severely decreased in the cerebral cortex of patients with AD [14] . These experimental ®ndings led us to propose the hypothesis that sGC activation and cGMP formation in the brain would improve task acquisition in cognitively impaired animals. We further hypothesized that use of a novel nitrate, GT 715 (2,3-dinitrooxy-(2,3-bis-nitrooxypropyldisulfanyl)-propane), with good CNS bioavailabilty, would provide an agent for cGMP elevation. Nitrates, of which glyceryl trinitrate (GTN) is the archetype, are NO-mimetics that may function as NO donors on chemical or enzymatic reaction in vivo, termed mechanism-based biotransformation [15, 16] . Thus, these hypotheses were tested by evaluating the effects of GT 715 in an animal model of dementia; namely, scopolamine-induced impairment of task acquisition in the Morris water maze.
MATERIALS AND METHODS
Experimental animals: The experiments described in this study were carried out in accordance with the guidelines established by the Canadian Council on Animal Care, and were approved by the Queen's University Animal Care Committee.
Morris Water Maze: Adult, male Long±Evans rats (250± 300 g) were used to test spatial learning in the Morris water maze. A circular pool (1.83 m in diameter and 38 cm deep) was ®lled with water (218C) made opaque by the addition of 500 ml non-toxic white paint. A circular escape platform (25 cm high, 20 cm diameter) located about 2 cm below the water surface served as an escape from the water. The platform was placed in the center of one of the four pool quadrants away from the wall. Rats were given a total of 12 trials, grouped in three trial blocks (i.e. four trials/block; $5 min between blocks). A trial started with the rat being released into the pool facing the pool wall. For each trial block, rats were released from the four cardinal compass points by pseudo-random assignment. A trial lasted until the rat mounted the hidden platform, after which it was allowed to stay on the platform for 15 s. If a rat did not locate the platform after 60 s of swimming, it was manually guided to the platform and left there for 15 s before commencement of the next trial. The latency to locate the hidden platform was measured by an experimenter standing in a ®xed position relative to the pool. Different groups of rats received the following drug treatments: scopolamine (0.5 mg/kg, i.p) DMSO (1 ml/kg, s.c), scopolamine GT 715 (0.5±500 ìmol/kg, s.c.), scopolamine GTN (500 ìmol/kg, s.c), scopolamine tacrine (9-amino-1,2,3,4-tetrahydroacridine; 12 mg/kg, i.p.), saline DMSO (1 ml/ kg), saline GT 715 (2 mmol/kg). Scopolamine was always administered 25 min before testing, and drug or vehicle injections were given 5 min later (20 min before testing). All drugs were given in a volume of 1 ml/kg body weight.
Determination of hippocampal sGC activity: The preparation of crude hippocampal sGC and enzyme assay conditions are the same as those described previously for rat aorta [17] . In addition to the usual assay components, samples contained 1 mM L-cysteine and either GTN (1 ìM± 1 mM) or GT 715 (1 ìM±1 mM). Reactions were initiated by the addition of 32±42 ìg hippocampal supernatant protein and terminated by the addition of 0.9 ml of 50 mM sodium acetate (pH 4.0) followed by heating at 908C for 3 min. The cGMP was quantitated by radioimmunoassay and the protein content was determined using bovine serum albumin as the standard.
Data analysis: All data are expressed as mean AE s.e.m. The effects of drug treatment on scopolamine-impaired task acquisition in the Morris water maze were analyzed by 2-way ANOVA to determine the interaction between treatment and trial block. Subsequently, data within each trial block was analyzed by one-way, randomized design analysis of variance, followed by Newman±Keuls' post-hoc test for multiple comparisons. The effects of GT 715 and GTN on sGC activity were analyzed by the paired t-test.
RESULTS
Scopolamine-impaired learning in the Morris water maze: In vehicle-treated control animals, repeated training in the water maze results in acquisition of an escape response to the submerged/hidden platform (Fig. 1a) . Pretreatment of rats with a high dose of GT 715 (2 mmol/kg) had no effect on task acquisition in the Morris water maze (Fig.  1a) , suggesting that in normal animals even very high doses of this compound have no effect on cognitive and motor performance.
In the next set of experiments, scopolamine (0.5 mg/kg, i.p.) was given 25 min prior to the ®rst trial block, and GT 715 was administered s.c. 5 min after scopolamine. GT 715 improved task acquisition in scopolamine-pretreated animals in a time-and dose-dependent manner (Fig. 1b,c) . In scopolamine-impaired animals, two-way ANOVA revealed a signi®cant effect of drug treatment (F(6,147) (Fig. 1b) . However, by the third block of trials, GT 715-treated animals performed at a level that was not different from that of saline-pretreated control animals (F(7,56) 11.73, p , 0.0001, Fig. 1b,c ). Signi®cant improvement in task acquisition by scopolamine-impaired animals was evident at doses of GT 715 as low as 5 ìmol/ kg body weight (Fig. 1c) , and was maximal at 50 ìmol/kg body weight (Fig. 1c) . At this dose, GT 715-induced reversal of scopolamine-impaired performance in the Morris water maze was not statistically different from that produced by the cholinesterase inhibitor, tacrine. In contrast, GTN at doses as high as 500 ìmol/kg body weight did not improve task acquisition in scopolamine-pretreated animals (Fig. 1c) .
Hippocampal sGC activity: GT 715 and GTN exhibited differential effects on activation of crude sGC in broken cell preparations from rat hippocampus. Although both compounds increased enzyme activity in a concentrationdependent manner, maximal enzyme activation by GT 715 was $3-fold greater than that by GTN, and the EC 50 value for enzyme activation by GT 715 was $50% that of GTN (Fig. 2) .
DISCUSSION
Central cholinergic muscarinic receptor blockade produces profound cognitive impairments in human and animal subjects. Loss of cholinergic neurons, and subsequent de®cits in cholinergic neurotransmission in the hippocampus and cerebral cortex, is strongly correlated with clinical signs of cognitive impairment and dementia in AD patients [18] . Drug therapy aimed at boosting cholinergic neurotransmission via inhibition of acetylcholinesterase activity provides symptomatic relief in the early stages of the disease, when cognitive impairment is mild to moderate [19] . The use of cholinergic muscarinic antagonists, such as scopolamine, in animal models to mimic the cognitive impairment observed in AD is well established, and has proven to be a useful model system for understanding and developing treatment strategies for neurodegenerative diseases in humans [20] . We have found that a novel nitrate ester, GT 715, can reverse scopolamine-impaired performance in the Morris water maze. This effect is unlikely to be related to changes in cerebral blood¯ow, since GTN was ineffective. Previous studies in our laboratories have shown that GT 715 is at least one order of magnitude less potent than GTN at relaxing vascular smooth muscle (data not shown). In contrast, GT 715 was more effective than GTN for activation of hippocampal sGC (Fig. 2) and for increasing cGMP accumulation in hippocampal brain slices in vitro (data not shown). These data therefore suggest that the structure of nitrate esters may be engineered to result in tissue selectivity for sGC activation.
Acetylcholine is one of the main modulatory neurotransmitters in brain regions, such as the hippocampus and cerebral cortex, involved in learning and memory. In these brain regions the actions of acetylcholine mediated by activation of muscarinic receptors are primarily excitatory, and result from modulation of multiple different ionic conductances [21, 22] . In the hippocampus, cholinergic muscarinic receptor activation leads to increased tissue levels of cGMP [4] . Moreover, the inhibition of the slow afterhyperpolarizing current (a calcium-activated potassium conductance that underlies spike-frequency adaptation) induced by muscarinic receptor activation in hippocampal CA1 pyramidal neurons can be blocked by inhibitors of sGC and cGMP-dependent protein kinase G [22] . These data suggest that at least some of the neuromodulatory effects of acetylcholine in the brain involve the NO/sGC/cGMP signal transduction cascade.
Behavioural studies have demonstrated that NMDA receptors play an important role in both spatial working memory and long-term memory processes. Blockade of NMDA receptors, or inhibition of NOS activity, impairs performance in the Y-maze test, a model of spatial working memory [23] . Impairment in the Y-maze induced by NMDA receptor blockade could be reversed by intracerebroventricular administration of S-nitroso-N-acetylpenicillamine (an NO donor), L-arginine (the substrate for NOS), or dibutyrl-cGMP (a membrane permeant analog of cGMP) [23] . Taken together, the results of these studies suggest that both acetylcholine and glutamate activate receptor systems coupled to the NO/sGC/cGMP signal transduction cascade, and that this biochemical cascade is important for synaptic plasticity and the formation of memory. This idea is further supported by studies demonstrating that inhibition of NOS impairs performance in the water maze during acquisition with multiple trials per day [24, 25] .
CONCLUSION
We show for the ®rst time that a systemically administered nitrate ester that has increased ef®cacy and potency for activation of sGC in the brain, compared to GTN, can reverse the cognitive impairment caused by cholinergic muscarinic receptor blockade. It is well established that de®cits in cholinergic neurotransmission and NO-dependent sGC signal transduction occur in the brain of AD patients. The results of this study therefore suggest that stimulation of cerebral sGC activity may be an effective strategy to improve learning and memory performance in individuals in whom cognitive abilities are impaired by injury, disease, or ageing.
